Sandoz international

Index
Globenewswire

Sandoz Launches Renewable Energy Partnership to Cover Nearly 90% of Electricity Demand for European Operations

Globenewswire

Sandoz Delivers Strong H1 2025 Results, with Accelerated Sales Growth in the Second Quarter

Globenewswire

Sandoz Signs Non-binding Term Sheet with Evotec SE to Acquire its Just-Evotec Biologics in-house Development and Manufacturing Capabilities in Toulouse, France

Globenewswire

Sandoz Further Asserts Leadership in Biosimilars, Breaking Ground on New Slovenia Facility to Expand European Biosimilar Hub and Global Market Reach

Globenewswire

Sandoz Launches First and Only Interchangeable Denosumab Biosimilars in US, Providing New Affordable Treatment Options for Over 10 Million Patients[1]

Globenewswire

Sandoz Launches Pyzchiva® Autoinjector, First Commercially Available in Europe for Ustekinumab Biosimilars

Globenewswire

Sandoz Reports Q1 2025 Net Sales in Line with Company Expectations; Full-year Guidance Confirmed

Globenewswire

Sandoz Enters Global Collaboration License Agreement with Henlius to Commercialize Leading Oncology Therapy, Ipilimumab, in Multiple Indications

Globenewswire

[Corrected] Sandoz Files Antitrust Litigation Against Amgen Regarding Patient Access to Etanercept Biosimilar in the US

Globenewswire

Sandoz Files Antitrust Litigation Against Amgen Regarding Patient Access to Etanercept Biosimilar in the US

Globenewswire

Sandoz Strengthens its Balance Sheet By Issuing New Bonds to Repay Spin-off Term Loans, and Signs New USD 2 Billion Revolving Credit Facility

Globenewswire

Sandoz Reports Strong FY 2024 Results and Q4 2024 Sales

Globenewswire

Sandoz Launches Biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, Offering New Treatment for Around 12 Million Patients[1-4]

Globenewswire

Francisco Ballester to Retire; Peter Stenico Appointed President Region International

Globenewswire

Sandoz to Confirm Strategic Roadmap and Highlight Pipeline Catalysts at 43rd Annual J.P. Morgan Healthcare Conference

Globenewswire

Sandoz Takes Further Steps to Resolve Legacy US Generic Drug Antitrust Class Action Litigation

Globenewswire

Sandoz Receives European Commission Approval for Afqlir® (aflibercept), Further Strengthening Leading Biosimilar Portfolio

Globenewswire

Sandoz Reports Third-quarter and Nine-month 2024 Sales

Globenewswire

Sandoz Receives FDA Approval for Enzeevu™ (Aflibercept-abzv), Further Strengthening US Biosimilar Position

Globenewswire

Sandoz Reports Second-quarter Sales and Half-year 2024 Results

Globenewswire

Sandoz Launches Biosimilar Pyzchiva® (ustekinumab) Across Europe, to Treat Chronic Inflammatory Diseases

Globenewswire

FDA Approves Biosimilar Pyzchiva® (ustekinumab-ttwe), to be Commercialized by Sandoz in US

Globenewswire

Sandoz Receives European Commission Approval for Wyost® and Jubbonti®, the First and Only Biosimilars of Denosumab in Europe

Globenewswire

Sandoz Reports First Quarter 2024 Sales

Globenewswire

Shareholders Approve All Resolutions Proposed by Board of Directors at Annual General Meeting of Sandoz Group AG